Welcome to our dedicated page for Avalyn Pharma news (Ticker: AVLN), a resource for investors and traders seeking the latest updates and insights on Avalyn Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avalyn Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avalyn Pharma's position in the market.
Avalyn (NYSE:AVLN) announced April 27, 2026 the appointments of Adam Golden as General Counsel and Head of Business Development and Frank Salisbury as Senior Vice President, Commercial.
Adam Golden brings over 30 years of legal and business development experience including senior roles at Freshfields, Hogan Lovells, and Kaye Scholer. Frank Salisbury brings 24+ years of commercial leadership and prior launches of therapies including ESBRIET and WINREVAIR. The hires target clinical advancement and commercial readiness ahead of future commercialization.
Avalyn (NASDAQ:AVLN) appointed Jon Congleton to its Board of Directors on April 6, 2026. Congleton brings nearly 40 years of biopharma experience and current CEO experience at Mineralys, with expertise in commercial strategy and organizational leadership.
His appointment is positioned to support Avalyn's Phase 2 programs, MIST for AP01 and AURA for AP02, and preparation for late‑stage development and commercialization.
Avalyn (NASDAQ:AVLN) announced a peer-reviewed publication (BMC Pulmonary Medicine, March 25, 2026) reporting that quantitative HRCT imaging changes with inhaled AP01 (pirfenidone) correlated with lung function and quality-of-life improvements in Phase 1b ATLAS patients.
Key results: >70% of AP01 100 mg BID patients with baseline and Week 24 imaging showed stabilization or improvement in fibrosis score; QOL gains appeared by Week 8 and persisted to Week 48. Avalyn plans HRCT in upcoming Phase 2 MIST and AURA trials; additional longitudinal data expected mid-2026.